Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Medroxyprogesterone versus placebo after hysteroscopic polypectomy for endometrial polyp recurrence
IRCT20120215009014N543Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of medroxyprogesterone acetate and Placebo-COD Research Private Ltd in endometrial polyp (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoints: Uterine polyp recurrence, Average endometrial thickness and 1 more. Started Dec 2024; status: completed.
02
Drugs
medroxyprogesterone acetatePlacebo-COD Research Private Ltd
03
Conditions
endometrial polyp
Beyond the preview
Go deeper on IRCT20120215009014N543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N543.